Nucala (mepolizumab) Letter of Medical Necessity
Nucala (mepolizumab) requires documented blood eosinophilia and severe disease despite high-dose controller therapy. Missing eosinophil counts is the top denial reason.
FDA-Approved Indications
- ● severe eosinophilic asthma
- ● eosinophilic granulomatosis with polyangiitis (EGPA)
- ● hypereosinophilic syndrome
- ● chronic rhinosinusitis with nasal polyps
Why Nucala Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Eosinophil count not documented
- 2. High-dose ICS trial missing
- 3. Exacerbation history insufficient
What to Include in a Nucala Letter of Medical Necessity
Document indication, blood eosinophil count (typically ≥150 or ≥300 cells/μL), exacerbation history, prior ICS/LABA/LAMA, oral steroid dependence, and FEV1.
Key clinical evidence to cite:
- ✓ DREAM, MENSA, MUSCA, SIRIUS trials
Relevant guidelines:
- 📖 GINA Asthma Strategy
- 📖 ACR EGPA Guidelines
Nucala Prior Authorization Criteria
Standard criteria across major US payers for Nucala. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → High-dose ICS trial missing
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Nucala
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Nucala Prior Authorization FAQ
Why was my Nucala prior authorization denied?
The most common denial reasons for Nucala are: Eosinophil count not documented; High-dose ICS trial missing; Exacerbation history insufficient.
What should a Nucala Letter of Medical Necessity include?
Document indication, blood eosinophil count (typically ≥150 or ≥300 cells/μL), exacerbation history, prior ICS/LABA/LAMA, oral steroid dependence, and FEV1.
Which payers cover Nucala?
Nucala is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.